← Back to Search

Local Anesthetic

AG-920 for Local Anesthesia

Phase 3
Waitlist Available
Research Sponsored by American Genomics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two to four minutes following treatment (last drop) of imp
Awards & highlights

Study Summary

This trial is designed to compare the safety and efficacy of AG-920 ophthalmic solution to Proparacaine Hydrochloride Ophthalmic Solution in pediatric subjects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomization through study completion (up to 4 days following treatment)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization through study completion (up to 4 days following treatment) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Proportion of Participants in Which an Eye Exam Was Able to be Performed
Secondary outcome measures
Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Side effects data

From 2020 Phase 3 trial • 120 Patients • NCT04513652
53%
Instillation Site Pain
7%
Dysgeusia
7%
Conjunctival Hyperaemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
AG-920
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AG-920Experimental Treatment1 Intervention
Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.
Group II: ProparacaineActive Control1 Intervention
0.5% Proparacaine Hydrochloride
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AG-920
2022
Completed Phase 3
~570

Find a Location

Who is running the clinical trial?

American Genomics, LLCLead Sponsor
4 Previous Clinical Trials
504 Total Patients Enrolled
Martin Uram, MDStudy DirectorMedical Expert
4 Previous Clinical Trials
504 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population
2022. "A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05325853.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top